

**Fortis Healthcare Limited**

Tower-A, Unitech Business Park, Block-F,  
South City 1, Sector – 41, Gurgaon,  
Haryana – 122 001 (India)

Tel : 0124 492 1033

Fax : 0124 492 1041

**Emergency : 105010**

Email : [secretarial@fortishealthcare.com](mailto:secretarial@fortishealthcare.com)

Website : [www.fortishealthcare.com](http://www.fortishealthcare.com)

**FHL/SEC/2024-25**

**November 08, 2024**

**The National Stock Exchange of India Ltd.  
Scrip Symbol: FORTIS**

**BSE Limited  
Scrip Code:532843**

**Sub: Press Release and Earnings Presentation under Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015**

Dear Sir/Madam,

Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, please find enclosed herewith the press release and earnings presentation for the quarter and period ended on September 30, 2024.

The date and time of occurrence of event is November 8, 2024 at 17.41 Hours.

This is for your information and records.

Thanking You,  
Yours sincerely,

**For Fortis Healthcare Limited**

**Satyendra Chauhan  
Company Secretary & Compliance Officer  
ICSI Membership: A14783**

**Encl: a/a**

---

**FORTIS HEALTHCARE LIMITED**

Regd. Office : Fortis Hospital, Sector 62, Phase – VIII, Mohali – 160062  
Tel : 0172-5096001, Fax : 0172-5096221, CIN : L85110PB1996PLC045933

### **Fortis Healthcare announces Q2 FY25 Financial Results**

**Hospital Business Revenues increase 13.9% to INR 1,655 Cr; Operating EBITDA up 32.5% to INR 355 Cr, 21.4% Margin**

**Diagnostic Business Revenues at INR 334 Cr versus INR 317 Cr; Operating EBITDA up 28.8% to INR 80 Cr; 24% Margin**

**Consolidated Revenues increase 12.3% to INR 1,988 Cr; Operating EBITDA up 31.9% to INR 435 Cr, 21.9% Margin**

**Gurugram, November 08, 2024:** Fortis Healthcare Ltd. (“Fortis” or the “Company”), amongst India’s leading healthcare delivery companies, today announced its unaudited consolidated financial results for the quarter and half year ended September 30, 2024.

#### **Financial Snapshot**

<b>Consolidated (INR Cr)</b>	<b>Q2FY24</b>	<b>Q2FY25</b>	<b>% Change YoY</b>	<b>H1FY24</b>	<b>H1FY25</b>	<b>% Change YoY</b>
Revenue	1,770	1,988	12.3%	3,427	3,847	12.3%
Operating EBITDA	330	435	31.9%	603	777	29.0%
Operating EBITDA Margin	18.6%	21.9%		17.6%	20.2%	
Profit Before Tax (Before exceptional item)	229	321	40.1%	398	551	38.2%
Profit After Tax*	184	193	5.0%	308	367	19.2%
Profit After Tax after Minority Interest and Share in Associates*	174	176	1.6%	285	342	19.9%
Earnings per share (EPS)	2.30	2.34		3.78	4.53	

\*PAT includes an exceptional gain of INR 0.2 Cr in Q1FY25 and exceptional loss of INR 59.8 Cr in Q2FY25, both of which pertain primarily to the impairment movement in an associate company; exceptional net gain of INR 3.7 Cr in Q2FY24 relates to the divestment of the Vadapalani, Chennai facility in July 2023.

<b>Hospital Business (INR Cr)</b>	<b>Q2FY24</b>	<b>Q2FY25</b>	<b>% Change YoY</b>	<b>H1FY24</b>	<b>H1FY25</b>	<b>% Change YoY</b>
Revenue	1,453	1,655	13.9%	2,807	3,204	14.2%
Operating EBITDA	268	355	32.5%	474	642	35.4%
Operating EBITDA Margin	18.4%	21.4%		16.9%	20.0%	

<b>Diagnostic Business (INR Cr)</b>	<b>Q2FY24</b>	<b>Q2FY25</b>	<b>% Change YoY</b>	<b>H1FY24</b>	<b>H1FY25</b>	<b>% Change YoY</b>
Revenue (net)	317	334	5.1%	621	643	3.6%
Operating EBITDA	62	80	28.8%	129	135	5.4%
Operating EBITDA Margin	19.6%	24.0%		20.7%	21.1%	

### **Q2 FY25 Financial Highlights**

- Q2FY25 consolidated revenues were at INR 1,988.4 Cr, up 12.3% versus Q2FY24. The operating margins for the quarter were 21.9%, versus 18.6% in the corresponding previous period.
- Q2FY25 hospital business revenues grew 13.9% to INR 1,654.7 Cr as compared to INR 1,452.6 Cr in Q2FY24. Operating margins stood at 21.4% for the period versus 18.4% in the corresponding previous period.
- Q2FY25 diagnostic business gross revenues were at INR 372.5 Cr versus INR 360.3 Cr in Q2FY24.

### **Balance Sheet**

- The Company's net debt as of 30<sup>th</sup> September 2024 stood at INR 281 Cr with a Net Debt to EBITDA of 0.16x as compared to the 0.29x as on 30<sup>th</sup> September 2023 (basis Q2 annualized EBITDA). Net debt to equity was at 0.03x versus 0.05x as on 30<sup>th</sup> September 2023.

### **HOSPITAL BUSINESS HIGHLIGHTS**

KPIs	Q2 FY25	Q2 FY24	H1 FY24	H1 FY25
<b>Occupancy</b>	72%	69%	66%	70%
<b>ARPOB (INR/Cr p.a.)</b>	2.37	2.21	2.19	2.39
<b>ALOS (Days)</b>	4.20	4.20	4.20	4.18

- Revenue growth in the hospital business for the quarter was led by an increase in ARPOB of 7.6% and higher occupancy compared to the corresponding previous period.
- The performance of the hospital business was also positively impacted by the combined revenue of the Company's top 6 key medical specialties viz. Oncology, Gastroenterology, Neurosciences, Renal Sciences, Orthopedics and Cardiac Sciences growing 13.6% in Q2FY25 versus corresponding previous period.
- Key surgical procedure volumes performed across some of our focus specialties such as Neuro Sciences and Robotic Surgeries increased by 21% and 57% YoY.
- Revenues from digital channels viz website, mobile application and digital campaigns witnessed a 30.1% YoY growth and 4.5% QoQ in Q2 FY25. Digital revenues contributed 29.3% to overall hospital revenues versus 25.6% in Q2FY24.
- The company's key facilities such as Shalimar Bagh, Mohali, Mulund, Amritsar, Faridabad, Anandpur witnessed revenue growth of 25%, 21%, 20%, 17%, 15 and 15% respectively.



## **DIAGNOSTICS BUSINESS HIGHLIGHTS**

- Operating EBITDA margins (basis gross revenues) stood at 21.5% versus 17.2% in Q2FY24. Excluding one offs the operating EBITDA margins stood at 24.0% versus 22.7% in Q2 FY24.
- Operating EBITDA margins (basis gross revenues) for H1 FY25 were 18.9% compared to 18.3% in H1 FY24.
- Continuing with its network expansion strategy, primarily the addition of new customer touch points (CTPs); Total CTPs as on 30th September 2024 stood at 4085.
- In Q2 FY25, Agilus conducted ~11.11 Mn tests versus ~10.59 Mn tests in Q2 FY24.
- The preventive portfolio revenues in Agilus' overall revenues grew 20% in Q2FY25 and contributed 12% to the operating revenues versus 10% in Q2FY24.

**Commenting on the results for the quarter, Dr Ashutosh Raghuvanshi, MD and CEO, Fortis Healthcare stated,** "We have continued our positive momentum in Q2 with the hospital business contributing approximately 82% to our consolidated EBITDA. We are making good progress on our plans to add nearly 700 beds this fiscal year across key facilities, including Faridabad, Anandpur, Shalimar Bagh, and Noida. Commensurate with our expansion plans, our 350-bed Manesar facility which we acquired in FY24 was commissioned recently. Leveraging our robust balance sheet, we would actively pursue further inorganic growth opportunities in our focus geographic clusters."

He further added "Among our key specialties, Oncology and Neuro Sciences grew by a strong 19% and 17%, respectively, compared to the same period last year. As part of our ongoing efforts to enhance our medical infrastructure, FMRI introduced the first MR LINAC in North and Central India in September. On the diagnostics business we are moving ahead to consolidate our stake in Agilus by acquiring the 31.52% stake from the PE investors. The diagnostics business performance is witnessing a steady recovery with relatively improving topline growth and better EBITDA margins. However, the business is still impacted by rebranding expenses which we expect will taper off towards the end of the fiscal"

**About Fortis Healthcare Limited:** Fortis Healthcare Limited is a leading integrated healthcare delivery service provider in India. The healthcare verticals of the company primarily comprise hospitals, diagnostics and day care specialty facilities. Currently, the company operates 28 healthcare facilities (including JVs and O&M facilities). The Company's network comprises approximately 4,700 operational beds (including O&M beds) and 419 diagnostics labs.

### **DISCLAIMER**

*This press release may contain forward-looking statements based on the currently held beliefs and assumptions of the management of the Company, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, recipients of this press release are cautioned not to place undue reliance on these forward-looking statements. The Company assumes no responsibility to publicly amend, modify or revise any forward-looking statements, on the basis of any subsequent development, information or events, or otherwise. The information contained herein is subject to change without notice and past performance is not indicative of future results. The Company may alter, modify or otherwise change in any manner the content of this press release, without obligation to notify any person of such revision or changes.*

**For further details please contact:**  
**Anurag Kalra / Amit Mahendru**  
Investor Relations  
+91-9810109253 / +91-9891094323  
Fortis Healthcare Limited

**Ajeay Maharaj**  
Corporate Communication  
+91-9871798573  
Fortis Healthcare Limited





# FORTIS HEALTHCARE LIMITED

EARNINGS PRESENTATION – Q2 FY25 and H1 FY25

November 08, 2024

## DISCLAIMER

---

This presentation may not be copied, published, distributed or transmitted. The presentation has been prepared solely by the company.

Any reference in this presentation to “Fortis Healthcare Limited” shall mean, collectively, the Company and its subsidiaries. This presentation has been prepared for informational purposes only. This presentation does not constitute a prospectus, offering circular or offering memorandum and is not an offer or invitation to buy or sell any securities, nor shall part, or all, of this presentation form the basis of, or be relied on in connection with, any contract or investment decision in relation to any securities. Furthermore, this presentation is not and should not be construed as an offer or a solicitation of an offer to buy securities of the company for sale in the United States, India or any other jurisdiction.

Securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering in the United States may be made only by means of an offering document that may be obtained from the Company and that will contain detailed information about the Company and its management, as well as financial statements. Any offer or sale of securities in a given jurisdiction is subject to the applicable laws of that jurisdiction.

This presentation contains forward-looking statements based on the currently held beliefs and assumptions of the management of the Company, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, recipients of this presentation are cautioned not to place undue reliance on these forward-looking statements.

The Company assumes no responsibility to publicly amend, modify or revise any forward-looking statements, on the basis of any subsequent development, information or events, or otherwise. Unless otherwise stated in this presentation, the information contained herein is based on management information and estimates. The information contained herein is subject to change without notice and past performance is not indicative of future results. The Company may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such revision or changes.

By attending or assessing this presentation you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company.

Neither the delivery of this presentation nor any further discussions of the Company with any of the recipients shall, under any circumstances, create any implication that there has been no change in the affairs of the Company since that date.

# About Fortis Healthcare

## National Capital Region

- FMRI, Gurugram
- FEHI, New Delhi
- Shalimar Bagh
- Noida
- Vasant Kunj (O&M)
- Faridabad
- Manesar, Gurugram
- La Femme GK
- Def Col
- C-DOC
- Greater Noida (O&M)

1,786

## Punjab

- Mohali
- Ludhiana
- Ludhiana 2
- Amritsar

771

## Rajasthan

Jaipur

275

## Maharashtra

- Mulund
- Vashi
- Kalyan
- SL Raheja (O&M)

770

## Karnataka

### Bengaluru

- BG Road
- CG Road
- NagarBhavi
- Rajaji Nagar
- Richmond Road

630

## West Bengal

- Kolkata
- Anandpur
- FHKI & FMC

362

## Chhattisgarh

- Raigarh (O&M)

70



28 Healthcare Facilities\*



4,650 + Operational Beds^



6,700+ Doctors



~6,500 Nurses



23,000+ employees  
(including Agilus)



4 JCI Accredited



25 NABH Accredited/  
Certified

Amongst the  
most accredited  
healthcare  
network in India

Note: \*Manesar facility is operationalized now  
^Including O&M beds

Beds



# AGENDA

1. Clinical Excellence at Fortis
2. Performance Highlights
  - Earnings and Financial Summary – Q2 FY25 and H1 FY25
3. Performance Review - Hospital Business
4. Performance Review - Diagnostics Business
5. Appendix





# CLINICAL EXCELLENCE AT FORTIS

---

## KEY HIGHLIGHTS



# CLINICAL EXCELLENCE

- **Fortis Hospital, Mohali**, became the first hospital in north of Delhi NCR to perform Robotic Trans-Axillary Nipple Sparing Mastectomy with Implant Reconstruction Surgery on two patients. While the first patient was suffering from multifocal mucinous breast cancer, the other had multifocal locally advanced breast cancer post neoadjuvant chemotherapy.
- **Fortis Hospital, Vasant Kunj**, successfully treated a 39-year-old Kenyan woman suffering from facial nerve schwannoma, an extremely rare tumour that grows on the facial nerve, eventually causing facial weakness, headache as well as hearing and vision loss.
- **Fortis Hospital, Mohali**, conducted the first **PIPAC** (Pressurized Intraperitoneal Aerosolised Chemotherapy), a novel technique useful in advanced stage abdominal cancers, available at a select few centers in India.
- **Fortis Hospital, Mohali**, performed its first ever ABO incompatible Living Donor Liver Transplant in the North Region on a 49-year old male patient suffering from liver failure.

*\*Above data pertains to Q2FY25*



# AUGMENTING MEDICAL PROGRAMS

- **Fortis Hospital, Manesar, Gurugram**, a 350 bedded facility, commenced its operations in September 2024. The hospital offers entire spectrum of clinical services including all key specialties and latest state-of-the art medical equipment.
- **Fortis Memorial, Gurugram** launched North & Central India's first MR LINAC, a technology that integrates Magnetic Resonance Imaging (MRI) with high-energy radiation therapy to target and treat tumors with unparalleled precision.
- **Fortis Escorts, Okhla Road, Delhi**, launched Fortis Cancer Institute & Oncology Day Care that will offer comprehensive cancer care, combining advanced medical technology including advanced imaging, pathology labs, and radiation therapy.
- **Fortis Gurugram** achieved a significant milestone in genomic testing, reporting 110 myeloid NGS (Next-Generation Sequencing) samples, using advanced Genexus machine. The median turnaround time for myeloid NGS is 5.3 days compared to industry standard of 15+/-6 days.
- **Fortis Vasant Kunj** inaugurated the Department of Medical Genetics that will offer genetic counseling services along with diagnosis and management of genetic disorders.
- **Fortis CG Road** launched a Bone Marrow Transplant facility for treatment of hematological disorders and malignancies.





# **Q2FY25 and H1FY25**

## **PERFORMANCE HIGHLIGHTS**

## Q2FY25 SNAPSHOT

Consolidated Revenue

**1,988 Crores**

↑ 12.3%

Consolidated Op EBITDA

**435 Crores**

(21.9% Margin)

↑ 31.9%

Consolidated PBT<sup>1</sup>

**321 Crores**

↑ 40.1%

Consolidated PAT<sup>1</sup>

**253 Crores**

↑ 40.3%

Net Debt / (Cash)<sup>3</sup>

**281 Crores**

Net Debt to EBITDA<sup>2,3</sup>

**0.16x vs 0.29x**

1. Excluding exceptional items

2. Basis Q2FY25 annualized EBITDA; 3. Net Debt as on 30<sup>th</sup> Sep 2024

# H1FY25 SNAPSHOT

Consolidated Revenue

**3,847 Crores**

↑ 12.3%

Consolidated Op EBITDA

**777 Crores**

(20.2% Margin)

↑ 29.0%

Consolidated PBT<sup>1</sup>

**551 Crores**

↑ 38.2%

Consolidated PAT<sup>1</sup>

**426 Crores**

↑ 40.9%

Net Debt / (Cash)<sup>3</sup>

**281 Crores**

Net Debt to EBITDA<sup>2,3</sup>

**0.16x vs 0.29x**

1. Excluding exceptional items

2. Basis Q2FY25 annualized EBITDA; 3. Net Debt as on 30<sup>th</sup> Sep 2024







## Q2FY25 SNAPSHOT

- Hospital business revenues grew 13.9% to INR 1,655 Cr versus INR 1,453 Cr in Q2FY24
- Hospital Business Operating EBITDA stood at INR 355 Cr, up 32.5%; while operating margin was at 21.4% versus 18.4% in Q2FY24
- Q2FY25 hospital business ARPOB was at INR 2.37 Cr per annum vs INR 2.21 Cr in Q2FY24, up 7.6%; Surgical : Non-Surgical mix stood at 58:42, compared to 59:41 in Q2FY24.
- Occupancy for the quarter stood at 72% versus 69% in Q2FY24
- The company's diagnostics business reported gross revenues of INR 372.5 Cr versus INR 360.3 Cr in Q2FY24.
- Operating EBITDA Margin of the diagnostics business (basis gross revenues) stood at 21.5% versus 17.2% in Q2FY24.



# CONSOLIDATED EARNINGS SUMMARY – Q2FY25


All figures in INR Cr



- Q1FY25 PAT excludes exceptional gain of INR 0.2 Cr and Q2FY25 PAT excludes exceptional loss of 59.8 Cr, both of which pertain primarily to the impairment movement in an associate company
- Q2FY24 PAT excludes exceptional net gain of INR 3.7 Cr related to the divestment of the Vadapalani, Chennai facility in July 2023

# CONSOLIDATED EARNINGS SUMMARY – H1FY25

All figures in INR Cr.





\*H1FY24 PAT excludes exceptional net gain of INR 5.2 Cr related to the divestment of the Vadapalani, Chennai facility in July 2023 and reversal of impairment in an associate Company.

\*H1FY25 PAT excludes exceptional net loss of INR 59.6 Cr which pertains primarily to impairment movement in an associate Company

# CONSOLIDATED EARNINGS SUMMARY

All figures in INR Cr





# Q2FY25

## HOSPITAL BUSINESS HIGHLIGHTS

- Occupancy was at 72%, compared to 69% in Q2FY24. Occupied beds increased to 2,939 compared to 2,779 in Q2FY24, a growth of 5.8%.
- Revenue from focus specialties comprising Oncology, Gastroenterology, Neurosciences, Renal Sciences, Orthopaedics and Cardiac Sciences grew 13.6% and contributed 61% to overall hospital business revenues, similar to Q2 FY24.
- International Patient revenues grew 6% to INR 134 Cr in Q2FY25 vs INR 127 Cr in Q2FY24. The business contributed 7.7% to overall hospital business revenues versus 8.3% in Q2FY24 and 7.8% in Q1FY25.
- Company further strengthened its medical talent with the onboarding of specialists in the areas of Cardiac Sciences, Renal Sciences, Gastroenterology, Internal Medicine and Obstetrics & Gynecology.

### Key Performance Indicators






# Q2FY25

## DIAGNOSTIC BUSINESS HIGHLIGHTS

- Agilus reported gross revenue of INR 372.5 Cr in Q2 FY25 as compared to INR 360.3 Cr in Q2FY24. Revenues for Q1FY25 were at INR 343.5 Cr, resulting in QoQ growth of 8.4%.
- Operating EBITDA (basis gross revenues) stood at INR 80.0 Cr versus INR 62.1 Cr in Q2FY24 (21.5% versus 17.2% EBITDA margin) and versus INR 55.4 Cr in Q1FY25 (16.1% margin).
- Operating EBITDA before one-off expenses\* was at INR 89 Cr versus INR 82 Cr in Q2FY24 (24.0% versus 22.7% EBITDA margin basis gross revenues) and versus INR 60 Cr in Q1FY25 (17.6% margin basis gross revenues).



Note: One off expenses pertains primarily to rebranding cost in Q2FY24: For Q1FY25, one off expenses pertain primarily to both rebranding costs and provision related to certain government businesses. In Q2FY25 it primarily includes rebranding expenses, reversal of provision related to certain government business and a contingent consideration payment for an earlier lab acquisition

# OPERATING PERFORMANCE

## HOSPITAL BUSINESS

Particulars (INR Cr)	Hospital Business				
	Q2FY24	Q1FY25	Q2FY25	H1FY24	H1FY25
<b>Operating Revenue</b>	<b>1,453</b>	<b>1,549</b>	<b>1,655</b>	<b>2,807</b>	<b>3,204</b>
Revenue Growth vs LY	12.0%	14.4%	13.9%	12.7%	14.2%
<b>Reported EBITDA</b>	<b>289</b>	<b>295</b>	<b>369</b>	<b>498</b>	<b>664</b>
EBITDA growth vs LY	8.3%	41.9%	27.5%	4.8%	33.5%
<b>Margin</b>	<b>19.9%</b>	<b>19.1%</b>	<b>22.3%</b>	<b>17.7%</b>	<b>20.7%</b>
Adj: Other Income <sup>^</sup>	22	8	14	23	22
<b>Operating EBITDA</b>	<b>268</b>	<b>287</b>	<b>355</b>	<b>474</b>	<b>642</b>
<b>Margin</b>	<b>18.4%</b>	<b>18.5%</b>	<b>21.4%</b>	<b>16.9%</b>	<b>20.0%</b>

- Above financials includes financials of International entities which are part of Fortis group; mainly RHTTM.
- <sup>^</sup>Hospital business reported EBITDA for Q2FY24 and Q2FY25 includes other income primarily as a result of the dividend income received from the Company's majority owned (57%) subsidiary Agilus Diagnostics

# OPERATING PERFORMANCE

## DIAGNOSTIC BUSINESS

Particulars (INR Cr)	Diagnostic Business				
	Q2FY24	Q1FY25	Q2FY25	H1FY24	H1FY25
<b>Operating Revenue</b>	<b>360</b>	<b>343</b>	<b>372</b>	<b>703</b>	<b>716</b>
Revenue Growth vs LY		0.2%	3.4%		1.9%
<b>Reported EBITDA</b>	<b>68</b>	<b>60</b>	<b>87</b>	<b>140</b>	<b>147</b>
EBITDA growth vs LY		(16.8%)	27.9%		4.8%
<b>Margin</b>	<b>18.8%</b>	<b>17.6%</b>	<b>23.3%</b>	<b>19.9%</b>	<b>20.5%</b>
Adj: Other Income incl FX	6	5	7	12	11
<b>Operating EBITDA</b>	<b>62</b>	<b>55</b>	<b>80</b>	<b>128</b>	<b>135</b>
<b>Margin</b>	<b>17.2%</b>	<b>16.1%</b>	<b>21.5%</b>	<b>18.3%</b>	<b>18.9%</b>
Adj: One off expenses*	20	4 <sup>^</sup>	9	25	14
<b>Operating EBITDA before one off exp</b>	<b>82</b>	<b>60</b>	<b>89</b>	<b>153</b>	<b>149</b>
<b>Margin</b>	<b>22.7%</b>	<b>17.6%</b>	<b>24.0%</b>	<b>21.8%</b>	<b>21.0%</b>

- \*One off expenses pertain primarily to rebranding cost in Q2FY24; In Q2FY25 it primarily includes rebranding expenses, reversal of provision related to certain government business and a contingent consideration payment for an earlier lab acquisition.
- <sup>^</sup>For Q1FY25, one off expenses pertain primarily to rebranding costs and provision related to certain government businesses; These expenses have been adjusted for unclaimed balances written back (more than 3 years) that were INR 4.5 Cr during the quarter; Margin has been calculated by adjusting the same amount from Operating Revenue (Rs 339 Cr); same adjustment has been done for H1FY25
- Diagnostics business revenue is on Gross Basis; Diagnostic business Q2FY25 net revenue (net of inter company elimination) stood at INR 333.7 Cr versus INR 317.4 Cr in Q2FY24 and INR 309.5 Cr in Q1FY25.

# BALANCE SHEET (CONSOLIDATED)

September 30, 2024

Balance Sheet (INR Cr)	March 31, 2024	June 30, 2024	Sep 30, 2024
Shareholder's Equity	8,556	8,615	8,729
Debt	859	866	878
Lease Liabilities (Ind AS 116)*	297	298	309
<b>Total Capital Employed</b>	<b>9,711</b>	<b>9,779</b>	<b>9,916</b>
Net Fixed Assets (including intangibles & CWIP)	6,221	6,283	6,413
Goodwill	4,194	4,194	4,194
Investments	230	230	175
Cash and Cash Equivalents	595	557	597
Net Other Assets <sup>^</sup>	(1,529)	(1,485)	(1,464)
<b>Total Assets</b>	<b>9,711</b>	<b>9,779</b>	<b>9,916</b>
<b>Net Debt / (cash)</b>	<b>264</b>	<b>308</b>	<b>281</b>
<b>Net Debt to Equity</b>	<b>0.03x</b>	<b>0.04x</b>	<b>0.03x</b>

- *\*Pertains to lease liability on account of adoption of new accounting standard on leases w.e.f. April 1, 2019.*
- *Net Debt excludes lease liabilities*
- *Net Debt to EBITDA was at 0.16x vs 0.29x for Q2FY25 and Q2FY24 (basis annualized EBITDA of Q2FY25 and Q2FY24, respectively)*
- *<sup>^</sup>Includes PUT option liability pertaining to Agilus' 31.52% Stake held by private equity investors.*



# PERFORMANCE REVIEW


HOSPITALS BUSINESS



# REVENUE MIX


Q2FY24

Gross Revenue : INR 1,532 CR




Q1FY25

Gross Revenue : INR 1,633 CR



Q2FY25


Gross Revenue : INR 1,744 CR




■ Non Surgical Revenue    ■ Surgical Revenue

# SPECIALTY MIX

Q2FY24




Q2FY25




Specialties such as Pulmonology, Oncology, Neurology and Orthopedics witnessed revenue growth of 21%, 19%, 17% and 15%, respectively

# PAYOR MIX

## Q2FY24





## Q2FY25



# HOSPITAL BUSINESS PERFORMANCE – Q2FY25

All the key healthcare facilities continue to witness a YoY upward momentum in revenues\*



\*Note: Excluding Jaipur

## HOSPITAL MARGIN MATRIX

H1FY25

EBITDA	No of Facilities	Revenue Contribution	Operational beds	ARPOB (INR Cr)	Occupancy
20%-25%	10	71.8%	2467	2.68	73%
15% - 20%	3	9.0%	552	1.43	77%
10% - 15%	1	0.6%	46	1.58	58%
<10%	7	17.5%	983	2.11	58%

FY24\*

EBITDA	No of Facilities	Revenue Contribution	Operational beds	ARPOB (INR Cr)	Occupancy
20% - 25%	8	62.2%	1,998	2.56	72%
15% - 20%	5	13.4%	745	1.76	62%
10% - 15%	3	13.8%	640	1.89	70%
<10%	5	8.1%	551	1.81	50%

Note: \*FY24 numbers exclude Vadapalani, Malar facilities and include Ludhiana 2 facility





## **BEDS EXPANSION UPDATE**

---

# Key Ongoing Expansion Projects

Manesar Facility (~300 Beds)\* –  
Phase 1 Operationalized (~75 Beds)  
Expected Phase 2 Capacity Addition: H2FY25



Noida New Tower (~145 Beds) –  
Expected operationalization: Phase 1 H2FY25 (~50 Beds) |  
Phase 2 H1FY26



Faridabad New Tower (50 Beds) – Expected operationalization H2FY25



FMRI New Tower (220 Beds) – Expected operationalization H1FY26



Note: \*Manesar facility's total capacity is ~350 beds.  
In addition to the bed expansion in Manesar, Faridabad and Noida, capacity of approx. 80 beds has been added across Shalimar Bagh, Anandpur, NagarBhavi in H1FY25; An additional capacity of approx. 210 beds will be added across following facilities in H2FY25 - BG Road, FMRI, Shalimar Bagh and Anandpur.




# PERFORMANCE REVIEW

---

DIAGNOSTICS BUSINESS

# DIAGNOSTICS BUSINESS

- During Q2FY25, Agilus conducted 11.11 Mn tests, versus 10.59 Mn in Q2FY24. In Q1FY25 Agilus conducted 9.92 Mn tests.
- Agilus added 150+ Customer touchpoints to its network in Q2FY25. Total CTPs as on 30th September 2024 stood at 4085.
- Agilus' B2C: B2B revenue mix stood at 54:46 in the quarter vs 53:47 in Q2FY24.




\*Note: Gross additions


# QUARTERLY REVENUE MIX

Q2FY25


**Geographic mix**






**Product Mix**



**Segment Mix**





Q2FY24



Specialised Include Covid & Covid Allied tests



# QUATERLY KEY PERFORMANCE METRICS





# APPENDIX

---

## GROUP CONSOLIDATED P&L – Q2FY25

Particulars ( INR Cr)	Q2FY24	Q1FY25	Q2FY25
<b>Revenue from operations</b>	<b>1,769.9</b>	<b>1,858.9</b>	<b>1,988.4</b>
Other income	13.5	13.0	13.2
<b>Total income</b>	<b>1,783.5</b>	<b>1,871.9</b>	<b>2,001.6</b>
Expenses	1,439.8	1,516.4	1,553.6
<b>EBITDA*</b>	<b>343.7</b>	<b>355.5</b>	<b>448.1</b>
<b>Margin</b>	<b>19.4%</b>	<b>19.1%</b>	<b>22.5%</b>
Finance costs	31.8	35.3	36.4
Depreciation and amortisation expense	84.1	91.0	95.1
<b>PBT</b>	<b>227.7</b>	<b>229.3</b>	<b>316.6</b>
Share of profit / (loss) of associates and joint ventures (net)	1.3	0.6	4.2
<b>Net profit / (loss) before exceptional items and tax</b>	<b>229.0</b>	<b>229.9</b>	<b>320.8</b>
Exceptional gain/loss**	3.7	0.2	-59.8
<b>Profit / (loss) before tax from continuing operations</b>	<b>232.7</b>	<b>230.1</b>	<b>261.1</b>
Tax expense / (credit)	48.8	56.1	68.0
<b>Net profit / (loss) for the period from continuing operations</b>	<b>183.9</b>	<b>174.0</b>	<b>193.1</b>
<b>Profit / (loss) from continuing operations attributable to Owners of the company</b>	<b>173.7</b>	<b>166.0</b>	<b>176.5</b>

\*EBITDA includes other income, forex and exceptional/non-recurring expenses

\*\*Q2FY24 exceptional net gain related to the divestment of the Vadapalani, Chennai facility in July 2023.

\*\*Q1FY25 exceptional gain of INR 0.2 Cr and Q2FY25 exceptional loss of INR 59.8 Cr, pertain primarily to the impairment movement in an associate company

## GROUP CONSOLIDATED P&L – H1FY25

Particulars (INR Cr)	H1FY24	H1FY25
<b>Revenue from operations</b>	<b>3,427.4</b>	<b>3,847.3</b>
Other income	21.6	26.3
<b>Total income</b>	<b>3,449.0</b>	<b>3,873.5</b>
Expenses	2,824.7	3,069.9
<b>EBITDA*</b>	<b>624.3</b>	<b>803.6</b>
<b>Margin</b>	<b>18.2%</b>	<b>20.9%</b>
Finance costs	63.3	71.7
Depreciation and amortisation expense	163.4	186.1
<b>PBT</b>	<b>397.6</b>	<b>545.8</b>
Share of profit / (loss) of associates and joint ventures (net)	0.7	4.8
<b>Net profit / (loss) before exceptional items and tax</b>	<b>398.3</b>	<b>550.7</b>
Exceptional gain**	5.2	-59.6
<b>Profit / (loss) before tax from continuing operations</b>	<b>403.4</b>	<b>491.1</b>
Tax expense / (credit)	95.6	124.0
<b>Net profit / (loss) for the period from continuing operations</b>	<b>307.9</b>	<b>367.1</b>
<b>Profit / (loss) from continuing operations attributable to Owners of the company</b>	<b>285.5</b>	<b>342.4</b>

\*EBITDA includes other income, forex and exceptional/non-recurring expenses

\*\*H1FY24 exceptional net gain of INR 5.2 Cr relates to the divestment of the Vadapalani, Chennai facility in July 2023, and reversal of impairment in an associate Company

\*\*H1FY25 exceptional net loss of INR 59.6 Cr, pertains primarily to the impairment movement in an associate company



**THANK YOU**

---